Originally founded as a spin-off from New England Biolabs, Inc, in May 2013, Biohelix Corporation was acquired by Quidel Corporation. Biohelix Corporation had been developing nucleic acid technologies for molecular diagnostics. These included a simple, cost-effective molecular diagnostic system called IsoAmp® for infectious diseases that takes advantage of the simplicity of an isothermal reaction and a disposable vertical-flow detection device. The lead product, the IsoAmp® HSV Assay, received FDA clearance in September 2011 for detecting genital and oral herpes under a moderate complexity label. among other simple molecular diagnostic tests for the near patient setting, the firm offers in vitro diagnostic products, such as IsoAmp, an herpes simplex viruses (HSV) assay test for the direct, qualitative detection of HSV DNA in male and female genital and oral lesions. The company also provides isothermal nucleic acid amplification solutions, including Rapisome pWGA kit, a whole genome amplification solution; IsoAmpII tHDA kit, a target sequence amplification solution; IsoAmpIII tHDA kit, a robust target amplification solution; and BESt Cassette, an express strip amplicon detection cassette. In addition, it offers Primer Navigator, a DNA amplification enhancer; and helicases, including helicase dependant amplification platform and primase-based whole genome amplification platform. Further, the company provides amplification enhancer reagents to improve all types of nucleic acid amplification reactions
